Viscosupplementation involves injecting highly purified solutions of hyaluronic acid or hyaluronan into the knee joints of patients suffering from knee osteoarthritis. These injections help improve knee lubrication, cushioning, and protect cartilage.
The Viscosupplementation Market Is Estimated To Be Valued At USD 4.15 Bn In 2025 And Is Expected To Reach USD 7.11 Bn By 2032, Growing At A Compound Annual Growth Rate (CAGR) Of 8.0% From 2025 To 2032
Knee osteoarthritis is a debilitating condition causing pain and stiffness in knee joints. With rising geriatric population worldwide, the prevalence of knee osteoarthritis has increased significantly. Viscosupplementation Market Demand provides an effective non-surgical treatment option for knee osteoarthritis patients by supplementing synovial fluid viscosity in knee joints. It helps reduce pain and improves mobility for around 6-12 months without requiring surgery. The advantages of viscosupplementation over other treatments include its non-invasive nature, shorter recovery time compared to surgery, and ability to delay knee replacement surgery. The need for an effective non-surgical treatment for knee osteoarthritis is expected to fuel the growth of the viscosupplementation market.
Key Takeaways
Key players operating in the viscosupplementation market are Anika Therapeutics Inc., Seikagaku Corporation, Zimmer Biomet, Bioventus, Ferring B.V., Sanofi, Lifecore Biomedical, and LG Chem.
Growing geriatric population and rising incidence of knee osteoarthritis globally are major factors driving the demand for viscosupplementation. According to estimates, over 300 million people worldwide will be suffering from osteoarthritis by 2050.
Technological advancements in hyaluronic acid formulations with long duration of pain relief and ability to replace lost elasticity in knee joints are expanding the applications of viscosupplementation. New single-injection and three-injection product types promise better patient compliance over conventional multi-injection therapies.
Market Trends
Increasing preference for single-injection viscosupplements – Many market players are developing single-injection viscosupplement products containing large molecular weight hyaluronic acid to provide pain relief lasting 6 months and avoid multiple hospital visits.
Rising collaboration between market players – Companies are focusing on co-development through collaboration to develop advanced HA formulations with long-acting properties using novel drug delivery technologies.
Market Opportunities
Growing demand in developing countries – Emerging economies in Asia Pacific and Latin America with large aging populations offer lucrative opportunities for global players for technology transfers and local manufacturing.
Combination therapies – Combining viscosupplementation with platelet-rich plasma injections and orthobiologics presents a synergistic therapeutic approach with potential for better clinical outcomes.
Impact of COVID-19 on Viscosupplementation Market Growth
The Viscosupplementation market has witnessed disruption due to the outbreak of COVID-19 pandemic. Disruptions in supply chain, restrictions on non-essential medical procedures led to decline in demand initially. However, as the pandemic persists, demand is increasing for treatment of knee osteoarthritis. With work from home culture, more number of people are facing joint pain issues requiring treatment.
In the pre-COVID era, the market was growing steadily owing to increasing geriatric population suffering from osteoarthritis and rising awareness. The market growth was supported by new product launches with improved formulations for better efficacy and longer duration of pain relief. However, during the pandemic, as elective surgeries were postponed, the market experienced downturn in 2020.
Going forward, as vaccination drives are ongoing globally, the market is expected to rebound gradually. The demand is projected to surge faster than pre-pandemic levels. This is because persistent joint issues during prolonged sedentary lifestyle due to pandemic will require effective non-surgical treatment solutions. Companies are exploring new marketing strategies to promote viscosupplementation as preferred first line treatment. Technological advancements to develop single-injection long-lasting formulations would further aid growth.
In terms of geographical regions, North America holds dominant share in terms of value in viscosupplementation market. This is attributed to increasing prevalence of osteoarthritis, growing obese population and rising healthcare spending in the US. Europe follows next in terms of market share led by demand from countries like Germany, UK and France. On the other hand, Asia Pacific is the fastest growing region primarily driven by large patient pool and improving access to healthcare in China and India.
The Middle East & Africa region presents lucrative opportunities for viscosupplementation market players. Countries in this region are focused on increasing access to non-surgical treatments for joint disorders. Additionally, growing medical tourism industry attracts patients from other regions for musculoskeletal treatments including viscosupplementation.
Get More Insights On-Viscosupplementation Market
Get This Report In Japanese Language
Get This Report In Korean Language
About Author:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)